Cosa pensano i pazienti oncologici circa le cure di prossimità. Risultato della survey del Cipomo

Sandro Barni, Fabrizio Artioli(Roche (Switzerland)), Cinzia Ortega(Candiolo Cancer Institute), Rosa Rita Silva, Monica Giordano(Ospedale Sant'Anna), Bruno Daniele(Azienda Ospedaliera G.Rummo), Livio Blasi, Luisa Fioretto(Ospedale SS. Annunziata), C. Aschele(Ospedale San Carlo), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Vincenzo Montesarchio(CTO Hospital), Graziella Pinotti(Medica (Italy))

Recenti Progressi in Medicina

May 1, 2024

10.1701/4262.42402

Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

|The Lancet Oncology|2018|2.5k

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

|Journal of Clinical Oncology|2019|1.8k

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.1k

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

|Journal of Clinical Oncology|2011|763